認知症治療薬市場：適応症別、薬剤クラス別-2025-2030年の世界予測

認知症治療薬市場は、2023年に98億米ドルと評価され、2024年には107億8,000万米ドルに達すると予測され、CAGR 10.39％で成長し、2030年には195億8,000万米ドルに達すると予測されています。

認知症治療薬市場の範囲には、主にアルツハイマー病、血管性認知症、レビー小体型認知症、前頭側頭型障害などの認知症に関連する症状の治療と管理を目的とした様々な治療介入が含まれます。これらの薬剤の必要性は、認知症の世界の有病率の増加、認知度の向上、認知症による社会的・家族的負担を軽減する緊急の必要性によってもたらされています。最終用途は主に症状管理と疾患進行の抑制であり、病院、診療所、専門ケアセンターなどが含まれます。市場の成長は、人口の高齢化、バイオテクノロジーの進歩、研究開発投資の増加といった要因の影響を受けています。さらに、政府の取り組みやヘルスケアのインフラ整備が、マーケット拡大のカタリストとなっています。最近の潜在的なビジネスチャンスとしては、タウやベータアミロイドの蓄積など、病態の根底にあるプロセスをターゲットとする疾患修飾療法の開発や、認知リハビリをサポートすることを目的とした新たなデジタル治療薬が挙げられます。こうした機会を活用するため、利害関係者は個別化医療のアプローチに投資し、医薬品開発にAI技術を活用することが推奨されます。しかし、市場開拓は、薬剤開発の高コスト、規制当局の承認プロセスの長期化、認知症の異質性に起因する臨床試験デザインの課題といった制約に直面しています。さらに、既存の治療に関する安全性と有効性の懸念が障害となっています。これらの課題を克服するためには、学術界、産業界、規制機関の強力な協力が必要です。技術革新の可能性のある分野としては、早期発見のためのバイオマーカー研究、薬物療法と組み合わせた非薬理学的介入、新規治療標的としての腸脳軸の探索などがあります。市場の性質はダイナミックで競争的であり、急速な技術進歩と患者中心のケア重視の高まりを特徴としています。成功するためには、企業は適応性を優先し、満たされていないニーズを探求し続け、認知症管理のための全人的ソリューションを育成するためにパートナーシップを拡大すべきです。

市場力学：急速に進化する認知症治療薬市場の主要市場インサイトを公開

認知症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 老人人口の増加
  • アルツハイマー病有病率の増加
  • アルツハイマー病に対する政府の資金援助と啓発プログラム
• 市場抑制要因
  • 研究開発費の高騰
• 市場機会
  • 安全で信頼性の高い薬へのアクセスを提供することによるオンライン薬局サービスの継続的な人気拡大
  • 新薬や治療法の進歩
  • アルツハイマー病および関連する認知症の治療法およびバイオマーカー開発の進展による資金調達機会の創出
• 市場の課題
  • 複雑な病態と病因、早期発見のためのバイオマーカーがないこと

ポーターの5つの力：認知症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：認知症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、認知症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析認知症治療薬市場における競合情勢の把握

認知症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス認知症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、認知症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨認知症治療薬市場における成功への道筋を描く

認知症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化人口の増加
    • アルツハイマー病の罹患率の増加
    • アルツハイマー病に対する政府の資金援助と啓発プログラム
  • 抑制要因
    • 調査と医薬品開発にかかる高額な費用
  • 機会
    • 安全で信頼できる医薬品へのアクセスを提供することにより、オンライン薬局サービスの人気は継続的に高まっています。
    • 新しい薬や治療法の進歩
    • アルツハイマー病および関連認知症の治療法とバイオマーカーの開発を進めることで、資金調達の機会が生まれました。
  • 課題
    • 病理と病因が複雑で、病気の早期発見のためのバイオマーカーがない
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 認知症治療薬市場適応症別

• アルツハイマー病
• レビー小体型認知症
• パーキンソン病認知症
• 血管性認知症

第7章 認知症治療薬市場薬剤クラス別

• コリンエステラーゼ阻害剤
• グルタミン酸阻害剤
• MAO阻害剤

第8章 南北アメリカの認知症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の認知症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの認知症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Anavex Life Sciences Corp.
• AstraZeneca PLC
• Aurobindo Pharma Limited
• Biogen Inc.
• Eisai Co., Ltd
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Forest Laboratories, Inc.
• Janssen Global Services, LLC
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Quidel Corporation
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals International, Inc.
• Zydus Cadila

LIST OF FIGURES

• FIGURE 1. DEMENTIA DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. DEMENTIA DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DEMENTIA DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DEMENTIA DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LEWY BODY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PARKINSONS DISEASE DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MAO INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 23. CANADA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 24. CANADA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. CHINA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 36. CHINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. INDIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 38. INDIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. ITALY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 73. ITALY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. POLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 81. POLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. QATAR DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 83. QATAR DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 103. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Dementia Drugs Market was valued at USD 9.80 billion in 2023, expected to reach USD 10.78 billion in 2024, and is projected to grow at a CAGR of 10.39%, to USD 19.58 billion by 2030.

The scope of the dementia drugs market encompasses various therapeutic interventions designed to treat and manage symptoms associated with dementia, mainly Alzheimer's disease, vascular dementia, Lewy body dementia, and frontotemporal disorders. The necessity of these drugs is driven by the increasing prevalence of dementia globally, heightened awareness, and the urgent need to alleviate the societal and familial burdens of the disease. Applications primarily include symptom management and slowing disease progression, with end-use markets involving hospitals, clinics, and specialized care centers. Market growth is influenced by factors such as an aging population, advancements in biotechnology, and increased R&D investments. Furthermore, governmental initiatives and supportive healthcare infrastructure serve as catalysts for market expansion. Recent potential opportunities include the development of disease-modifying therapies that target underlying pathological processes, such as tau and beta-amyloid accumulations, as well as emerging digital therapeutics aiming to support cognitive rehabilitation. To capitalize on these opportunities, stakeholders are encouraged to invest in personalized medicine approaches and leverage AI technologies in drug development. However, the market faces limitations like high costs of drug development, lengthy regulatory approval processes, and challenges in clinical trial designs due to the heterogeneous nature of dementia. Moreover, safety and efficacy concerns regarding existing treatments present obstacles. Overcoming these challenges requires strong collaboration between academia, industry, and regulatory bodies. Potential areas for innovation include biomarker research for early detection, non-pharmacological interventions paired with pharmacotherapy, and exploring the gut-brain axis as a novel therapeutic target. The nature of the market is dynamic and competitive, characterized by rapid technological advancements and a growing emphasis on patient-centric care. To thrive, companies should prioritize adaptability, continue exploring unmet needs, and expand partnerships to foster holistic solutions for dementia management.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dementia Drugs Market

The Dementia Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing geriatric population base
  • Increase in prevalence of Alzheimer disease
  • Government funding & awareness programs for Alzheimer disease
• Market Restraints
  • High costs of research and drug development
• Market Opportunities
  • Continuous growth in popularity of online pharmacy services due to providing safe and reliable access to medication
  • Advancement of new drugs and treatments
  • Advancing therapeutic and biomarker development for Alzheimer's and related dementias created funding opportunities
• Market Challenges
  • Complex pathology and etiology and no biomarkers for early detection of the disease

Porter's Five Forces: A Strategic Tool for Navigating the Dementia Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dementia Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dementia Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dementia Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dementia Drugs Market

A detailed market share analysis in the Dementia Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dementia Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dementia Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dementia Drugs Market

A strategic analysis of the Dementia Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dementia Drugs Market, highlighting leading vendors and their innovative profiles. These include Anavex Life Sciences Corp., AstraZeneca PLC, Aurobindo Pharma Limited, Biogen Inc., Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., Janssen Global Services, LLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Quidel Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Dementia Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indications, market is studied across Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia, and Vascular Dementia.
• Based on Drug Class, market is studied across Cholinesterase Inhibitors, Glutamate Inhibitors, and MAO Inhibitors.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing geriatric population base
    • 5.1.1.2. Increase in prevalence of Alzheimer disease
    • 5.1.1.3. Government funding & awareness programs for Alzheimer disease
  • 5.1.2. Restraints
    • 5.1.2.1. High costs of research and drug development
  • 5.1.3. Opportunities
    • 5.1.3.1. Continuous growth in popularity of online pharmacy services due to providing safe and reliable access to medication
    • 5.1.3.2. Advancement of new drugs and treatments
    • 5.1.3.3. Advancing therapeutic and biomarker development for Alzheimer's and related dementias created funding opportunities
  • 5.1.4. Challenges
    • 5.1.4.1. Complex pathology and etiology and no biomarkers for early detection of the disease
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dementia Drugs Market, by Indications

• 6.1. Introduction
• 6.2. Alzheimer's Disease
• 6.3. Lewy Body Dementia
• 6.4. Parkinsons Disease Dementia
• 6.5. Vascular Dementia

7. Dementia Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Cholinesterase Inhibitors
• 7.3. Glutamate Inhibitors
• 7.4. MAO Inhibitors

8. Americas Dementia Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Dementia Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Dementia Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Anavex Life Sciences Corp.
• 2. AstraZeneca PLC
• 3. Aurobindo Pharma Limited
• 4. Biogen Inc.
• 5. Eisai Co., Ltd
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche AG
• 8. Forest Laboratories, Inc.
• 9. Janssen Global Services, LLC
• 10. Merck & Co., Inc.
• 11. Novartis AG
• 12. Pfizer, Inc.
• 13. Quidel Corporation
• 14. Sanofi S.A.
• 15. Teva Pharmaceutical Industries Ltd.
• 16. Valeant Pharmaceuticals International, Inc.
• 17. Zydus Cadila